An error occurred retrieving publication content to display, please try again.
Page not found (404)
Sorry - the page you requested could not be found.
Please choose a page from the navigation or try a website search above to find the information you need.
Toolkit
Review evidence suggests that the most cost-effective treatment approach for the prevention of future occlusive vascular events is: in ischaemic stroke/transient ischaemic attack patients is clopidogrel (CLOP) followed by modified-release dipyridamole plus aspirin (ASA) and then ASA alone; in myocardial infarct (heart attack) patients is ASA followed by CLOP; and for patients with established peripheral arterial disease or multivascular disease is CLOP followed by ASA
1 Liverpool Reviews and Implementation Group (LRiG), University of Liverpool, Liverpool, UK
2 North West Medicines Information Centre, Pharmacy Practice Unit, Liverpool, UK
3 The Institute for Cardiovascular and Medical Sciences, Liverpool Heart and Chest Hospital, Liverpool, UK
* Corresponding author Email: Janette.Greenhalgh@liv.ac.uk
Funding: {{metadata.Funding}}
{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}
https://doi.org/{{metadata.DOI}}
Citation:{{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al. ' : ''}}. {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})
Report Content
The full text of this issue is available as a PDF document from the Toolkit section on this page.
The full text of this issue is available as a PDF document from the Toolkit section on this page.
Responses to this report
No responses have been published.
An error has occurred in processing the XML document